IL98770A - Peptides, analogues and mixtures thereof, methods for the detection of I-VLTH and II-VLTH antiviral antibodies and pharmaceutical preparations containing them - Google Patents

Peptides, analogues and mixtures thereof, methods for the detection of I-VLTH and II-VLTH antiviral antibodies and pharmaceutical preparations containing them

Info

Publication number: IL98770A
Authority: IL; Israel
Prior art keywords: htlv; peptide; bch; amino acids; immunogenic
Prior art date: 1990-07-18

Application number

IL9877091A

Other languages

English (en)

Hebrew (he)

Other versions

IL98770A0 (en

Original Assignee

Iaf Biochem Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-07-18

Filing date

1991-07-09

Publication date

1996-10-16

1991-03-20 Priority claimed from US07/672,483 external-priority patent/US5359029A/en

1991-07-09 Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int

1992-07-15 Publication of IL98770A0 publication Critical patent/IL98770A0/xx

1996-10-16 Publication of IL98770A publication Critical patent/IL98770A/en

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 245
102000004196 processed proteins & peptides Human genes 0.000 title claims description 106
239000000203 mixture Substances 0.000 title claims description 66
238000000034 method Methods 0.000 title claims description 37
241000700605 Viruses Species 0.000 title description 14
239000008194 pharmaceutical composition Substances 0.000 title description 2
150000001413 amino acids Chemical class 0.000 claims description 78
230000008878 coupling Effects 0.000 claims description 39
238000010168 coupling process Methods 0.000 claims description 39
238000005859 coupling reaction Methods 0.000 claims description 39
230000002163 immunogen Effects 0.000 claims description 26
230000000890 antigenic effect Effects 0.000 claims description 25
125000001424 substituent group Chemical group 0.000 claims description 25
239000000427 antigen Substances 0.000 claims description 21
102000036639 antigens Human genes 0.000 claims description 21
108091007433 antigens Proteins 0.000 claims description 21
101800000385 Transmembrane protein Proteins 0.000 claims description 19
238000003556 assay Methods 0.000 claims description 19
108010078428 env Gene Products Proteins 0.000 claims description 19
101800001271 Surface protein Proteins 0.000 claims description 17
102100034353 Integrase Human genes 0.000 claims description 16
101710177291 Gag polyprotein Proteins 0.000 claims description 14
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims description 14
101710205625 Capsid protein p24 Proteins 0.000 claims description 13
101710177166 Phosphoprotein Proteins 0.000 claims description 13
101710149279 Small delta antigen Proteins 0.000 claims description 13
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 claims description 13
210000004899 c-terminal region Anatomy 0.000 claims description 13
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
101710125418 Major capsid protein Proteins 0.000 claims description 12
238000002965 ELISA Methods 0.000 claims description 9
239000012491 analyte Substances 0.000 claims description 8
208000015181 infectious disease Diseases 0.000 claims description 8
241000124008 Mammalia Species 0.000 claims description 7
208000036142 Viral infection Diseases 0.000 claims description 4
230000028993 immune response Effects 0.000 claims description 4
244000052769 pathogen Species 0.000 claims description 4
230000009385 viral infection Effects 0.000 claims description 4
230000001717 pathogenic effect Effects 0.000 claims description 3
239000002671 adjuvant Substances 0.000 claims description 2
239000003623 enhancer Substances 0.000 claims description 2
230000035931 haemagglutination Effects 0.000 claims description 2
241000714259 Human T-lymphotropic virus 2 Species 0.000 claims 10
241000714260 Human T-lymphotropic virus 1 Species 0.000 claims 8
235000001014 amino acid Nutrition 0.000 description 53
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
239000000523 sample Substances 0.000 description 27
210000002966 serum Anatomy 0.000 description 24
238000002474 experimental method Methods 0.000 description 23
239000011347 resin Substances 0.000 description 19
229920005989 resin Polymers 0.000 description 19
108090000623 proteins and genes Proteins 0.000 description 17
238000012360 testing method Methods 0.000 description 15
102000004169 proteins and genes Human genes 0.000 description 14
239000000243 solution Substances 0.000 description 14
235000018102 proteins Nutrition 0.000 description 13
125000006239 protecting group Chemical group 0.000 description 12
229960005486 vaccine Drugs 0.000 description 12
210000004369 blood Anatomy 0.000 description 11
239000008280 blood Substances 0.000 description 11
241000598436 Human T-cell lymphotropic virus Species 0.000 description 10
238000001514 detection method Methods 0.000 description 10
230000035945 sensitivity Effects 0.000 description 9
239000007790 solid phase Substances 0.000 description 9
208000005599 HTLV-I Infections Diseases 0.000 description 8
125000003275 alpha amino acid group Chemical group 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 8
102000013415 peroxidase activity proteins Human genes 0.000 description 8
108040007629 peroxidase activity proteins Proteins 0.000 description 8
238000006467 substitution reaction Methods 0.000 description 8
208000007687 HTLV-II Infections Diseases 0.000 description 7
108700004025 env Genes Proteins 0.000 description 7
101150030339 env gene Proteins 0.000 description 7
239000000047 product Substances 0.000 description 7
239000011534 wash buffer Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
125000000539 amino acid group Chemical group 0.000 description 6
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 6
239000000126 substance Substances 0.000 description 6
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 5
201000006966 adult T-cell leukemia Diseases 0.000 description 5
108700004026 gag Genes Proteins 0.000 description 5
101150098622 gag gene Proteins 0.000 description 5
230000008105 immune reaction Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000011002 quantification Methods 0.000 description 5
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
238000005406 washing Methods 0.000 description 4
VHYRLCJMMJQUBY-UHFFFAOYSA-N 1-[4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCC1=CC=C(N2C(C=CC2=O)=O)C=C1 VHYRLCJMMJQUBY-UHFFFAOYSA-N 0.000 description 3
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
208000027814 HTLV-2 infection Diseases 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
206010044696 Tropical spastic paresis Diseases 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000012237 artificial material Substances 0.000 description 3
-1 benzotriazol-l-yloxy-tris (dimethylamino) phosphonium hexafluoro-phosphate Chemical compound 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000009260 cross reactivity Effects 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
239000011521 glass Substances 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000036039 immunity Effects 0.000 description 3
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 3
239000012071 phase Substances 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
239000012064 sodium phosphate buffer Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
208000006961 tropical spastic paraparesis Diseases 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
102100034349 Integrase Human genes 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
208000000389 T-cell leukemia Diseases 0.000 description 2
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000010836 blood and blood product Substances 0.000 description 2
229940125691 blood product Drugs 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000013611 chromosomal DNA Substances 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
201000009277 hairy cell leukemia Diseases 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
229920006370 Kynar Polymers 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
FXAGBTBXSJBNMD-UHFFFAOYSA-N acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FXAGBTBXSJBNMD-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
238000010640 amide synthesis reaction Methods 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
229940025131 amylases Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229920000592 inorganic polymer Polymers 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
IOPLHGOSNCJOOO-UHFFFAOYSA-N methyl 3,4-diaminobenzoate Chemical compound COC(=O)C1=CC=C(N)C(N)=C1 IOPLHGOSNCJOOO-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
108010091748 peptide A Proteins 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000006069 physical mixture Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
101150088264 pol gene Proteins 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000005373 porous glass Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000001566 pro-viral effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
101150034499 rex2 gene Proteins 0.000 description 1
230000007017 scission Effects 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
238000002764 solid phase assay Methods 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
ZERULLAPCVRMCO-UHFFFAOYSA-N sulfure de di n-propyle Natural products CCCSCCC ZERULLAPCVRMCO-UHFFFAOYSA-N 0.000 description 1
229940126577 synthetic vaccine Drugs 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
230000008719 thickening Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
235000002374 tyrosine Nutrition 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000004474 valine Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

IL9877091A 1990-07-18 1991-07-09 Peptides, analogues and mixtures thereof, methods for the detection of I-VLTH and II-VLTH antiviral antibodies and pharmaceutical preparations containing them IL98770A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55425890A	1990-07-18	1990-07-18
US07/672,483 US5359029A (en)	1990-07-18	1991-03-20	Peptides and analogues and mixtures thereof for detecting antibodies to HTLV-I and HTLV-II viruses

Publications (2)

Publication Number	Publication Date
IL98770A0 IL98770A0 (en)	1992-07-15
IL98770A true IL98770A (en)	1996-10-16

Family

ID=27070535

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9877091A IL98770A (en)	1990-07-18	1991-07-09	Peptides, analogues and mixtures thereof, methods for the detection of I-VLTH and II-VLTH antiviral antibodies and pharmaceutical preparations containing them

Country Status (15)

Country	Link
EP (1)	EP0539405B1 (de)
JP (1)	JP3390002B2 (de)
AP (1)	AP9100296A0 (de)
AT (1)	ATE124419T1 (de)
AU (1)	AU658144B2 (de)
CA (1)	CA2087436C (de)
CS (1)	CS221391A3 (de)
DE (1)	DE69110891T2 (de)
ES (1)	ES2076538T3 (de)
IE (1)	IE912497A1 (de)
IL (1)	IL98770A (de)
MX (1)	MX9100257A (de)
NZ (1)	NZ238855A (de)
PT (1)	PT98356B (de)
WO (1)	WO1992001713A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04164097A (ja) *	1990-10-24	1992-06-09	Kuraray Co Ltd	ペプチドおよびその用途
DK0677117T3 (da) *	1991-07-10	1999-11-29	Abbott Lab	Sondring mellem HTLV-I og HTLV-II under anvendelse af syntetiske peptider
CA2100883A1 (en) *	1991-11-25	1993-05-26	Dade International Inc.	Immunoassay using synthetic htlv-ii peptides
DE69330164T2 (de) *	1992-02-24	2002-01-17	Genelabs Technologies, Inc.	Htlv-i/htlv-ii assay und verfahren
EP0698214A1 (de) *	1994-03-02	1996-02-28	Abbott Laboratories	Hiv immunoassay unter verwendung rekombinanter proteine und synthetischer peptidreagenzien
US5888763A (en) *	1994-12-30	1999-03-30	The Rockefeller University	Peptides specific for the first Crk-SH3 domain
JP6519478B2 (ja) *	2013-11-06	2019-05-29	富士レビオ株式会社	抗ｈｔｌｖ抗体の免疫測定における非特異反応の低減方法
EP2913338A1 (de)	2014-02-28	2015-09-02	Roche Diagniostics GmbH	Lösliche und immunoreaktive Varianten von HTLV-Antigen-Kapsid P24
CN110672844A (zh) *	2019-10-29	2020-01-10	华中科技大学	一种新城疫病毒抗体磁免疫化学发光检测试剂盒及其应用
CN116037072B (zh) *	2023-02-24	2025-01-03	宁夏医科大学	一种血清抗体亲和分离材料的制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0107053B1 (de) *	1982-09-30	1989-09-13	Japanese Foundation For Cancer Research	Menschliche dem Leukämie-Virus verwandte Peptiden, deren Antikörper und Verfahren zu deren Herstellung
US5017687A (en) *	1988-03-10	1991-05-21	Virovahl, S.A.	Peptides for the detection of HTLV-1 infection
DE69015708T2 (de) *	1989-01-13	1995-06-08	United Biomedical Inc., Lake Success, N.Y.	Künstliche peptid-zusammensetzungen mit immunoreaktiven antikörpern von htlv-1.
SE8900721D0 (sv) *	1989-03-02	1989-03-02	Blomberg Jonas	Methods for detection of antibodies to

1991
- 1991-07-05 NZ NZ238855A patent/NZ238855A/en not_active IP Right Cessation
- 1991-07-09 IL IL9877091A patent/IL98770A/en not_active IP Right Cessation
- 1991-07-10 JP JP51159191A patent/JP3390002B2/ja not_active Expired - Fee Related
- 1991-07-10 AU AU82119/91A patent/AU658144B2/en not_active Ceased
- 1991-07-10 ES ES91912338T patent/ES2076538T3/es not_active Expired - Lifetime
- 1991-07-10 WO PCT/CA1991/000238 patent/WO1992001713A1/en not_active Ceased
- 1991-07-10 EP EP91912338A patent/EP0539405B1/de not_active Expired - Lifetime
- 1991-07-10 DE DE69110891T patent/DE69110891T2/de not_active Expired - Fee Related
- 1991-07-10 CA CA002087436A patent/CA2087436C/en not_active Expired - Lifetime
- 1991-07-10 AT AT91912338T patent/ATE124419T1/de not_active IP Right Cessation
- 1991-07-17 PT PT98356A patent/PT98356B/pt not_active IP Right Cessation
- 1991-07-17 CS CS912213A patent/CS221391A3/cs unknown
- 1991-07-17 AP APAP/P/1991/000296A patent/AP9100296A0/en unknown
- 1991-07-17 IE IE249791A patent/IE912497A1/en unknown
- 1991-07-18 MX MX9100257A patent/MX9100257A/es unknown

Also Published As

Publication number	Publication date
ATE124419T1 (de)	1995-07-15
CA2087436A1 (en)	1992-01-19
JPH05508838A (ja)	1993-12-09
DE69110891D1 (de)	1995-08-03
AU8211991A (en)	1992-02-18
EP0539405A1 (de)	1993-05-05
JP3390002B2 (ja)	2003-03-24
IL98770A0 (en)	1992-07-15
CS221391A3 (en)	1992-02-19
MX9100257A (es)	1992-02-28
EP0539405B1 (de)	1995-06-28
AU658144B2 (en)	1995-04-06
CA2087436C (en)	2001-04-17
PT98356B (pt)	1999-01-29
WO1992001713A1 (en)	1992-02-06
IE912497A1 (en)	1992-01-29
PT98356A (pt)	1992-06-30
ES2076538T3 (es)	1995-11-01
DE69110891T2 (de)	1996-03-14
NZ238855A (en)	1994-03-25
AP9100296A0 (en)	1991-07-31

Legal Events

Date	Code	Title
1997-03-18	FF	Patent granted
1997-11-20	KB	Patent renewed
2001-06-14	RH	Patent void
2001-08-26	KB	Patent renewed
2005-09-25	KB	Patent renewed
2010-04-08	KB	Patent renewed
2012-02-29	EXP	Patent expired

Publication	Publication Date	Title
US5574132A (en)	1996-11-12	Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
JPH0751598B2 (ja)	1995-06-05	Ｈｔｌｖ‐１感染検出用合成ペプチド抗原
EP0539405B1 (de)	1995-06-28	Peptide und analoge und mischungen davon zum nachweis der gegen die viren htlv-1 und htlv-ii gerichteten antikörper
EP0538283B2 (de)	2001-08-01	Synthetische peptide und mischungen davon zum nachweis der gegen hiv-gerichteten antikörper
AU629528B2 (en)	1992-10-08	Synthetic peptides and mixtures thereof for detecting hiv antibodies
AU638727B2 (en)	1993-07-08	Peptides and antibodies derived therefrom for the diagnosis of, therapy for and vaccination against htlv-1 infection
EP0605433B1 (de)	1995-12-27	IMMUNTEST ZUM GLEICHZEITIGEN NACHWEIS VON HIV-1, HIV-2, HTLV-I und HTLV-II ANTIKÖRPERN
AU646641B2 (en)	1994-03-03	Rubella peptides
US5359029A (en)	1994-10-25	Peptides and analogues and mixtures thereof for detecting antibodies to HTLV-I and HTLV-II viruses
CA1341594C (en)	2009-04-21	Synthetic peptides and mixtures therof for detecting hiv antibodies
WO1994023746A1 (en)	1994-10-27	Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
US6218102B1 (en)	2001-04-17	Synthetic peptides and mixtures thereof for detecting HIV antibodies